Gen Surg SAQs · applied-science
Thresholds, risk scores, trial choice, and lifelong follow-up
Fellowship SAQ on Eisenberg BMI thresholds, OS-MRS scoring, SLEEVEPASS/SM-BOSS sleeve-versus-bypass numbers with reflux and conversion, Mingrone/STAMPEDE remission durability, weight-adjusted VTE prophylaxis, and 10-year nutrition.
On this page
Study tools
Target exams
Write your answer
Saved on this device. No marking — you are the marker.
(A) Indications and mortality scoring (4 marks). Offer surgery at BMI over 35 regardless of comorbidity and consider it at 30-34.9 with metabolic disease; both vignette patients qualify — the woman by recommendation, and class I consideration applies from BMI 30 with disease.[8] Score the man at OS-MRS 5 of 5: BMI 50 or more, male, hypertension, PE-risk history, age 45 or more at one point each — derivation mortality 7.56 percent class C against 0.31 class A, validated at 2.4 against 0.2 percent across 4,431 bypasses with class C carrying twelvefold mortality.[9][10] Consent him as the highest-risk stratum, not as a routine bypass.[10]
(B) Sleeve versus bypass (3 marks). Quote SLEEVEPASS 5 years: excess weight loss 49 percent sleeve against 57 percent bypass with equivalence failed on the minus 9 to plus 9 margins; diabetes tied 37 against 45 percent; morbidity 19 against 26 percent.[13] Quote SM-BOSS 5 years: weight a statistical draw (61.1 against 68.3 percent) but reflux remission 60.4 against 25.0 percent favouring bypass with worsening 6.3 against 31.8 percent.[14] For the refluxing, regaining sleeved patient add the conversion ledger: sleeve-to-other-anatomy conversion 29.9 against 5.5 percent beyond 10 years with more de-novo reflux after sleeve — revise, do not repeat the sleeve.[17]
(C) Durability, clots, food (3 marks). Counsel the woman with Mingrone 5 years (50 percent surgical remission held, relapse in 53 percent of bypass and 37 percent of BPD 2-year remitters — surveilled, not cured) and STAMPEDE 5 years (HbA1c 6.0 or less 5 percent medical against 29 percent bypass and 23 percent sleeve).[19][21] Dose heparin by weight: 0.54 against 2.0 percent VTE with bleeding level at 1.6 against 2.3 percent.[28] Book lifelong nutrition: deficiencies rare but iron worse after bypass (41 against 14 percent) with sleeve adherence lower (71 against 89 percent) — iron watched after bypass, adherence chased after sleeve, nobody discharged.[37]
References10ShowHide
- [8]Eisenberg D, et al. 2022 American Society of Metabolic and Bariatric Surgery (ASMBS) and International Federation for the Surgery of Obesity and Metabolic Disorders (IFSO) Indications for Metabolic and Bariatric Surgery. Obes Surg, 2023.PMID 36336720
- [9]DeMaria EJ, et al. Obesity surgery mortality risk score: proposal for a clinically useful score to predict mortality risk in patients undergoing gastric bypass. Surg Obes Relat Dis, 2007.PMID 17386394
- [10]DeMaria EJ, et al. Validation of the obesity surgery mortality risk score in a multicenter study proves it stratifies mortality risk in patients undergoing gastric bypass for morbid obesity. Ann Surg, 2007.PMID 17893494
- [13]Salminen P, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss at 5 Years Among Patients With Morbid Obesity: The SLEEVEPASS Randomized Clinical Trial. JAMA, 2018.PMID 29340676
- [14]Peterli R, et al. Effect of Laparoscopic Sleeve Gastrectomy vs Laparoscopic Roux-en-Y Gastric Bypass on Weight Loss in Patients With Morbid Obesity: The SM-BOSS Randomized Clinical Trial. JAMA, 2018.PMID 29340679
- [17]Kraljevic M, et al. Long-Term Outcomes of Laparoscopic Roux-en-Y Gastric Bypass vs Laparoscopic Sleeve Gastrectomy for Obesity: The SM-BOSS Randomized Clinical Trial. JAMA Surg, 2025.PMID 39969869
- [19]Mingrone G, et al. Bariatric-metabolic surgery versus conventional medical treatment in obese patients with type 2 diabetes: 5 year follow-up of an open-label, single-centre, randomised controlled trial. Lancet, 2015.PMID 26369473
- [21]Schauer PR, et al. Bariatric Surgery versus Intensive Medical Therapy for Diabetes - 5-Year Outcomes. N Engl J Med, 2017.PMID 28199805
- [28]Ikesaka R, et al. Efficacy and safety of weight-adjusted heparin prophylaxis for the prevention of acute venous thromboembolism among obese patients undergoing bariatric surgery: a systematic review and meta-analysis. Thromb Res, 2014.PMID 24508449
- [37]Saarinen I, et al. Nutritional deficiencies after sleeve gastrectomy and Roux-en-Y gastric bypass at 10 years: secondary analysis of the SLEEVEPASS randomized clinical trial. Br J Surg, 2025.PMID 40613787